Efficacy and safety of different doses of evolocumab in reducing low-density lipoprotein cholesterol levels: A meta-analysis
C Cheng, S Sun, Y Zhou, X Yang - Biomedical Reports, 2016 - spandidos-publications.com
Evolocumab has been considered as an efficacious, safe and promising therapeutic
modality for hypercholesterolemia and is associated with cardiovascular diseases. The …
modality for hypercholesterolemia and is associated with cardiovascular diseases. The …
Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis
Aims Although alirocumab and evolocumab have both been associated with improved
outcomes in patients with dyslipidaemia or established atherosclerotic cardiovascular …
outcomes in patients with dyslipidaemia or established atherosclerotic cardiovascular …
Safety of evolocumab use in clinical practice in subjects with severe hyperlipemia and statins intolerance
B Napolitano, V Napolitano, L Napolitano… - …, 2021 - atherosclerosis-journal.com
Methods: We wanted to verify, in patients suffering from severe hyperlipemia and with
demonstrated intolerance to statins (at least two treatments with different statins), the safety …
demonstrated intolerance to statins (at least two treatments with different statins), the safety …
Profile of evolocumab and its cost-effectiveness in patients with high cardiovascular risk: literature review
SM Janković, D Tešić, J Anđelković… - Expert Review of …, 2018 - Taylor & Francis
Introduction: Evolocumab is fully human monoclonal antibody which binds to proprotein
convertase subtilisin/kexin type 9 (PCSK9), and prevents its blocking effect on recycling of …
convertase subtilisin/kexin type 9 (PCSK9), and prevents its blocking effect on recycling of …
Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
Objective The FOURIER trial showed a benefit of the PCSK9 inhibitor evolocumab over
placebo with respect to cardiovascular outcomes in patients with cardiovascular disease …
placebo with respect to cardiovascular outcomes in patients with cardiovascular disease …
Cost-effectiveness analysis of evolocumab in adult patients with atherosclerotic cardiovascular disease in Canada
J Grégoire, S Champsi, M Jobin, L Martinez… - Advances in …, 2022 - Springer
Introduction To evaluate the cost-effectiveness of evolocumab when added to standard of
care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease …
care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease …
Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease
D Steffens, P Bramlage, J Müller, C Dorn, WD Paar… - Open …, 2021 - openheart.bmj.com
Background Atherosclerotic cardiovascular disease is the leading cause of death and
disability in the Western world. Objective To characterise adults with confirmed coronary …
disability in the Western world. Objective To characterise adults with confirmed coronary …
two yeaR analysis of tHe safety anD toleRability of evolocuMab: tHe osleR-1 stuDy
MJ Koren, R Giugliano, F Raal, D Sullivan… - Journal of the American …, 2015 - jacc.org
Background: The OSLER-1 study previously reported that SC evolocumab, a monoclonal
antibody against PCSK9, markedly lowered and maintained LDL-C levels with a favorable …
antibody against PCSK9, markedly lowered and maintained LDL-C levels with a favorable …
THE OSLER-2 STUDY: PATIENTS'PREFERENCES AND COMPLIANCE WITH BIWEEKLY OR MONTHLY DOSING DURING TREATMENT OF …
MJ Koren, C Djedjos, Y Ma, R Somaratne… - Journal of the American …, 2016 - jacc.org
Background The OSLER-2 study previously reported that evolocumab, a monoclonal
antibody directed against PCSK9, markedly lowered levels of LDL-C and other lipoproteins …
antibody directed against PCSK9, markedly lowered levels of LDL-C and other lipoproteins …
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the …
Aims To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and
safety of alirocumab, a fully human monoclonal antibody to proprotein convertase …
safety of alirocumab, a fully human monoclonal antibody to proprotein convertase …